Forgettable in the care of liver cirrhosis: the unseen culprits of progression from bad to worse

被引:0
作者
Elsabaawy, Maha [1 ]
Alhaddad, Omkosoum [1 ]
机构
[1] Menoufia Univ, Natl Liver Inst, Dept Hepatol & Gastroenterol, Shibin Al Kawm, Menoufia, Egypt
来源
GASTROENTEROLOGY REVIEW-PRZEGLAD GASTROENTEROLOGICZNY | 2024年 / 19卷 / 01期
关键词
cirrhosis; liver disease; nutrition; fibrosis; PROTON PUMP INHIBITORS; VITAMIN-D DEFICIENCY; ACUTE KIDNEY INJURY; HEPATIC-ENCEPHALOPATHY; DIABETES-MELLITUS; HEPATOCELLULAR-CARCINOMA; CLINICAL-IMPLICATIONS; SODIUM RESTRICTION; DISEASE; RISK;
D O I
10.5114/pg.2024.136361
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Patients with liver cirrhosis constitute a critically ill and unique population, and their stability relies on a well -coordinated multidisciplinary team with a carefully structured plan. Overlooking any aspect of this plan can expedite disease progression, leading to severe complications. The lack of disease -specific nutritional guidance, the prevalent sedentary lifestyle among patients, and insufficient screening for hepatocellular carcinoma, oesophageal varices, sarcopaenia, minimal hepatic encephalopathy, and diabetes mellitus, along with fibrosis progression and cirrhosis decompensation, can add further complexities. Additionally, devaluing the impact of obesity in triggering liver cirrhosis can be disadvantageous. Prolonged and inappropriate use of proton pump inhibitors also poses a significant challenge with a wide range of complications. These often -unheeded aspects in the care of liver cirrhosis patients represents the unseen culprits of progression from bad to worse and warrant serious consideration.
引用
收藏
页码:6 / 17
页数:12
相关论文
共 9 条
  • [1] ASK1/p38 axis inhibition blocks the release of mitochondrial "danger signals" from hepatocytes and suppresses progression to cirrhosis and liver cancer
    Peng, Zhenwei
    Wei, Guangyan
    Huang, Pinzhu
    Matta, Heansika
    Wen, Gao
    An, Ping
    Zhao, Shuangshuang
    Lin, Yi
    Tan, Li
    Vaid, Kahini
    Skelton-Badlani, Disha
    Nasser, Imad
    Budas, Grant
    Lopez, David
    Li, Li
    Breckenridge, David
    Myers, Rob
    McHutchison, John
    Kuang, Ming
    Popov, Yury V.
    HEPATOLOGY, 2024, 80 (02) : 346 - 362
  • [2] Progression from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis Cirrhosis Confirmed by Liver Histology after 14 Years
    Kawanaka, Miwa
    Nishino, Ken
    Morimoto, Yumiko
    Ishii, Katsunori
    Tanikawa, Tomohiro
    Urata, Noriyo
    Suehiro, Mitsuhiko
    Sasai, Takako
    Haruma, Ken
    Kawamoto, Hirofumi
    INTERNAL MEDICINE, 2021, 60 (09) : 1397 - 1401
  • [3] Serum Cytokine Analysis Reveals Predictors of Progression from Chronic Hepatitis B to Liver Cirrhosis
    Cai, F.
    Zhao, Y.
    Chen, Q.
    Hu, Y.
    Su, S.
    Lu, Y.
    FOLIA BIOLOGICA, 2021, 67 (01) : 28 - 36
  • [4] Inflammation in background cirrhosis evokes malignant progression in HCC development from HCV-associated liver cirrhosis
    Tarao, Kazuo
    Ohkawa, Shinichi
    Miyagi, Yohei
    Morinaga, Soichiro
    Ohshige, Kenji
    Yamamoto, Naoto
    Ueno, Makoto
    Kobayashi, Satoshi
    Kameda, Ryo
    Tamai, Setsuo
    Nakamura, Yoshiyasu
    Miyakawa, Kaoru
    Kameda, Yoichi
    Okudaira, Masahiko
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2013, 48 (06) : 729 - 735
  • [5] Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin
    Ng, Khai-Jing
    Tseng, Chih-Wei
    Chang, Ting-Tsung
    Tzeng, Shinn-Jia
    Hsieh, Yu-Hsi
    Hung, Tsung-Hsing
    Huang, Hsiang-Ting
    Wu, Shu-Fen
    Tseng, Kuo-Chih
    CLINICAL INTERVENTIONS IN AGING, 2016, 11 : 1035 - 1041
  • [6] Number needed to screen to prevent progression of liver fibrosis to cirrhosis at primary health centers: An experience from Delhi
    Nagappa, Bharathnag
    Ramalingam, Archana
    Rastogi, Aayushi
    Dubey, Shantanu
    Thomas, Sherin Sarah
    Gupta, Ekta
    Sarin, Shiv Kumar
    JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2021, 10 (03) : 1412 - 1418
  • [7] Factors Associated with Progression to Hepatocellular Carcinoma and to Death from Liver Complications in Patients with HBsAg-Positive Cirrhosis
    Tong, Myron John
    Hsien, Carlos
    Song, Joanna Jungeun
    Kao, Jia Horng
    Sun, Hai-En
    Hsu, Leeyen
    Han, Steven-Huy
    Durazo, Francisco Antonio
    Saab, Sammy
    Blatt, Lawrence Mitchell
    DIGESTIVE DISEASES AND SCIENCES, 2009, 54 (06) : 1337 - 1346
  • [8] Factors Associated with Progression to Hepatocellular Carcinoma and to Death from Liver Complications in Patients with HBsAg-Positive Cirrhosis
    Myron John Tong
    Carlos Hsien
    Joanna Jungeun Song
    Jia Horng Kao
    Hai-En Sun
    Leeyen Hsu
    Steven-Huy Han
    Francisco Antonio Durazo
    Sammy Saab
    Lawrence Mitchell Blatt
    Digestive Diseases and Sciences, 2009, 54 : 1337 - 1346
  • [9] Taurocholic acid is an active promoting factor, not just a biomarker of progression of liver cirrhosis: evidence from a human metabolomic study and in vitro experiments
    Liu, Zhimin
    Zhang, Zhifeng
    Huang, Mei
    Sun, Xiaoping
    Liu, Bojia
    Guo, Qiyang
    Chang, Qingshan
    Duan, Zhijun
    BMC GASTROENTEROLOGY, 2018, 18